https://doi.org/10.4081/hmr.v1i9.320

Fibrinolytics, enzyme inhibitors, and cancer survival

Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005
Published: June 3, 2009
Abstract Views: 156
PDF: 645
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Schmitt
support@pagepress.org
V Magdolen
K Mengele
U Reuning
J Foekens
EP Diamandis
N Harbeck
The majority of cancer patients do not die from their primary tumor but from disseminated tumor cells traversing through the body to form distant metastases.1,2 As one of the initial steps in this process, tumors secrete the vascular permeability factor VEGF that prompts the neighboring microvasculature to become permeable to fibrinogen and to other plasma proteins.3,4 Extravasated plasma-derived fibrinogen is rapidly cleaved by the serine protease thrombin to generate cross-linked fibrin, a process which also constitutes the final step in the intravascular blood coagulation cascade.5-8

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Schmitt, M., Magdolen, V., Mengele, K., Reuning, U., Foekens, J., Diamandis, E., & Harbeck, N. (2009). Fibrinolytics, enzyme inhibitors, and cancer survival. Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.320
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).